Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care

Tim J R Lambert and John W Newcomer
Med J Aust 2009; 190 (4): 39.
  • Tim J R Lambert1,2
  • John W Newcomer3

  • 1 Brain and Mind Research Institute, University of Sydney, Sydney, NSW.
  • 2 Concord Medical School, University of Sydney, Sydney, NSW.
  • 3 Department of Psychiatry, Washington University School of Medicine, St Louis, Mo, USA.


Competing interests:

Tim Lambert has received grant support from Janssen, Pfizer, Bristol-Myers Squibb, and Eli Lilly. He is a consultant and/or on speakers’ bureaus for Janssen, Pfizer, Bristol-Myers Squibb, AstraZeneca, Eli Lilly, Novartis and Hospira. John Newcomer has received grant/research support from the US National Institute of Mental Health, the National Alliance for Research on Schizophrenia and Depression, the Sidney R Baer Jr Foundation, Janssen, Pfizer, Bristol-Myers Squibb and Wyeth. He is a consultant for Janssen, Pfizer, Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, Organon, Solvay, Wyeth, and consultant to litigation for Compact Clinicals.

  • 1. Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J Clin Psychiatry 2007; 68 Suppl 4: 4-7.
  • 2. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150: 1115-1121.
  • 3. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007; 68 Suppl 4: 8-13.
  • 4. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997; 171: 502-508.
  • 5. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64: 1123-1131.
  • 6. Bobes J, Arango C, Aranda P, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007; 90: 162-173.
  • 7. Cohn T, Prud’homme D, Streiner D, et al. Characterising coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004; 49: 753-761.
  • 8. Holt RIG, Peveler RC. Association between antipsychotic drugs and diabetes. Diabetes Obes Metab 2006; 8: 125-135.
  • 9. Baskar V, Kamalakannan D, Holland MR, Singh BM. Does ethnic origin have an independent impact on hypertension and diabetic complications? Diabetes Obes Metab 2006; 8: 214-219.
  • 10. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13 Suppl 1: 1-68.
  • 11. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68 Suppl 1: 20-27.
  • 12. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006; 51: 492-501.
  • 13. Morrato EH, Newcomer JW, Allen RR, Valuck RJ. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J Clin Psychiatry 2008; 69: 316-322.
  • 14. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006; 86: 15-22.
  • 15. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA 2007; 298: 1794-1796.
  • 16. Phelan M, Stradins L, Morrison S. Physical health of people with severe mental illness. BMJ 2001; 322: 443-444.
  • 17. Lambert TJR, Chapman L, Group CW. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004; 181: 544-548. <MJA full text>
  • 18. Buckley PF, Miller DD, Singer B, et al. Clinicians’ recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 2005; 79: 281-288.
  • 19. Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004; 24: S1-S6.
  • 20. Barnes TR, Paton C, Cavanagh MR, et al. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull 2007; 33: 1397-1403.
  • 21. Haupt DW, Fahnestock PA, Flavin KA, et al. Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. Neuropsychopharmacology 2007; 32: 2561-2569.
  • 22. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case–control study. Lancet 2005; 366: 1640-1649.
  • 23. Jennex A, Gardner DM. Monitoring and management of metabolic risk factors in outpatients taking antipsychotic drugs: a controlled study. Can J Psychiatry 2008; 53: 34-42.
  • 24. Sernyak MJ. Implementation of monitoring and management guidelines for second-generation antipsychotics. J Clin Psychiatry 2007; 68 Suppl 4: 14-18.
  • 25. Goldman LS. Medical illness in patients with schizophrenia. J Clin Psychiatry 1999; 60: 10-15.
  • 26. Druss BG, Bradford WD, Rosenheck RA, et al. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry 2001; 58: 565-572.
  • 27. Anath J. Physical illness and psychiatric disorders. Compr Psychiatry 1984; 25: 586-593.
  • 28. Roick C, Fritz-Wieacker A, Matschinger H, et al. Health habits of patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2007; 42: 268-276.
  • 29. Jeste DV, Gladsjo JA, Lindamer LA, Lacro JP. Medical comorbidity in schizophrenia. Schizophr Bull 1996; 22: 413-430.
  • 30. Horvitz-Lennon M, Kilbourne AM, Pincus HA. From silos to bridges: meeting the general health care needs of adults with severe mental illnesses. Health Aff (Millwood) 2006; 25: 659-669.
  • 31. Lambert TJR, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust 2003; 178 (9 Suppl): S67-S70. <MJA full text>
  • 32. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212-217.
  • 33. Kim MM, Swanson JW, Swartz MS, et al. Healthcare barriers among severely mentally ill homeless adults: evidence from the five-site health and risk study. Adm Policy Ment Health 2007; 34: 363-375.
  • 34. Druss BG. Improving medical care for persons with serious mental illness: challenges and solutions. J Clin Psychiatry 2007; 68 Suppl 4: 40-44.
  • 35. Lai DW, Chau SB. Effects of service barriers on health status of older Chinese immigrants in Canada. Soc Work 2007; 52: 261-269.
  • 36. Druss BG, von Esenwein SA. Improving general medical care for persons with mental and addictive disorders: systematic review. Gen Hosp Psychiatry 2006; 28: 145-153.
  • 37. Lambert BL, Cunningham FE, Miller DR, et al. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am J Epidemiol 2006; 164: 672-681.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.